Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004
Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbact...
Saved in:
Published in | International journal of antimicrobial agents Vol. 30; no. 5; pp. 452 - 457 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Elsevier B.V
01.11.2007
Amsterdam Elsevier New York, NY |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7–100%) and A. baumannii (66.0–86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9–86.6% in Southern China and 64.8–82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved ≤50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa . Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China. |
---|---|
AbstractList | Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved <=50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China. Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved < or =50% CFR against all bacterial species. Meropenem 2g every 8h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China. Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7–100%) and A. baumannii (66.0–86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9–86.6% in Southern China and 64.8–82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved ≤50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa . Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China. Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7–100%) and A. baumannii (66.0–86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9–86.6% in Southern China and 64.8–82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved ≤50% CFR against all bacterial species. Meropenem 2 g every 8 h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China. Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals, a 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for cefoperazone/sulbactam, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem and meropenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa collected during 2003 and 2004. The carbapenems had the highest CFRs against the Enterobacteriaceae (94.7-100%) and A. baumannii (66.0-86.3%). Ceftazidime, meropenem and cefoperazone/sulbactam obtained the greatest CFRs against P. aeruginosa (73.9-86.6% in Southern China and 64.8-82.1% in Northern China). All other cephalosporin and ciprofloxacin regimens achieved < or =50% CFR against all bacterial species. Meropenem 2g every 8h as a 3-h infusion displayed ca. 90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China. |
Author | Ni, Yuxing Chen, Minjun Nicolau, David P Wang, Hui Chen, Baiyi Zhang, Bo Kuti, Joseph L |
Author_xml | – sequence: 1 fullname: Wang, Hui – sequence: 2 fullname: Zhang, Bo – sequence: 3 fullname: Ni, Yuxing – sequence: 4 fullname: Kuti, Joseph L – sequence: 5 fullname: Chen, Baiyi – sequence: 6 fullname: Chen, Minjun – sequence: 7 fullname: Nicolau, David P |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19163889$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17646088$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk-LFDEQxYOsuLOrX0HiQW895k93kr4IMqyrsKCgnkN1uno2Y3d6TTIDc_Gzm2YGVrzoqerwq1fFe3VFLsIckJBXnK054-rtbu13ELKfvIPtWjCm10ytGWuekBU3WlS65fKCrFgr6so0ur0kVyntGOONrJtn5JJrVStmzIr8-nIPcQI398cARY9miFvMFHIGHyYMmc4DTXjAQM8r49x5GBOFbSFSprcRpirgFrI_IO3AZYweqJvHEUvf0yHOE93c-wDUB1rOlUWqX5r6OXk6FC18ca7X5PuHm2-bj9Xd59tPm_d3lWsanSvsVCew5mbopXaAgxSiZZpp3hjDhwY1OGlki6IXPRs6VrdOqhpN17O-M05ekzcn3Yc4_9xjynbyyeE4QsB5n6wyshHFqH-CvFVc1rUqYHsCix8pRRzsQ_QTxKPlzC4p2Z39IyW7pGSZsiWlMvvyvGTfTdg_Tp5jKcDrMwDJwThECM6nR67lShqzXLs5cVi8O3iMNjmPwWHvY_He9rP_r3Pe_aXiRh8KNv7AI6bdvI-hhGO5TcIy-3V5q-WrSgBMaNHI3y4qzaE |
CitedBy_id | crossref_primary_10_1007_s10156_011_0271_9 crossref_primary_10_1155_2021_1175379 crossref_primary_10_2133_dmpk_DMPK_11_RG_027 crossref_primary_10_1038_s41598_024_60909_7 crossref_primary_10_1097_IPC_0000000000000141 crossref_primary_10_1179_1973947814Y_0000000214 crossref_primary_10_1179_1973947815Y_0000000078 crossref_primary_10_1002_phar_2505 crossref_primary_10_1128_AAC_00385_20 crossref_primary_10_1186_cc11405 crossref_primary_10_1186_cc11459 crossref_primary_10_1016_j_micpath_2019_103809 crossref_primary_10_1128_AAC_00126_11 crossref_primary_10_1186_1471_2334_10_171 crossref_primary_10_1016_j_ijantimicag_2008_08_023 crossref_primary_10_1345_aph_1P187 crossref_primary_10_1016_j_ijantimicag_2019_06_021 crossref_primary_10_1111_bcp_15819 crossref_primary_10_1007_s11096_018_0720_y crossref_primary_10_1007_s10156_009_0001_8 crossref_primary_10_1016_j_cmi_2020_11_032 crossref_primary_10_1345_aph_1M339 crossref_primary_10_3390_antibiotics10080993 crossref_primary_10_1016_j_heliyon_2024_e32600 |
Cites_doi | 10.1086/516284 10.1097/01.inf.0000094940.81959.14 10.1016/j.ijantimicag.2006.07.014 10.1016/j.diagmicrobio.2005.04.004 10.1086/510590 10.1016/j.diagmicrobio.2005.10.004 10.1016/j.diagmicrobio.2004.09.001 10.1128/AAC.45.1.13-22.2001 10.1592/phco.27.3.333 |
ContentType | Journal Article |
Copyright | Elsevier B.V. and the International Society of Chemotherapy 2007 Elsevier B.V. and the International Society of Chemotherapy 2007 INIST-CNRS |
Copyright_xml | – notice: Elsevier B.V. and the International Society of Chemotherapy – notice: 2007 Elsevier B.V. and the International Society of Chemotherapy – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T7 8FD C1K FR3 P64 7X8 |
DOI | 10.1016/j.ijantimicag.2007.06.005 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Bacteriology Abstracts (Microbiology B) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Engineering Research Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1872-7913 |
EndPage | 457 |
ExternalDocumentID | 10_1016_j_ijantimicag_2007_06_005 17646088 19163889 S0924857907002725 1_s2_0_S0924857907002725 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Asia China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMG HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LUGTX M29 M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SIN SPCBC SSH SSI SSZ T5K UNMZH WUQ XPP Z5R ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR ABPIF ABPTK IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T7 8FD C1K FR3 P64 7X8 |
ID | FETCH-LOGICAL-c557t-eb6b2e418fd37caef3229070715881f5e7ac3839e2d2d0fb049c364e8bd0db8c3 |
IEDL.DBID | .~1 |
ISSN | 0924-8579 |
IngestDate | Thu Oct 24 23:45:38 EDT 2024 Sat Oct 26 00:53:17 EDT 2024 Thu Sep 26 19:04:53 EDT 2024 Sat Sep 28 07:43:37 EDT 2024 Sun Oct 22 16:04:13 EDT 2023 Fri Feb 23 02:34:42 EST 2024 Tue Oct 15 22:55:10 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Antibiotic Pharmacodynamics Bacterial resistance Infection Resistance Target Targeting Bacteriosis Antibacterial agent Biological activity Antimicrobial agent Gram negative bacteria |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c557t-eb6b2e418fd37caef3229070715881f5e7ac3839e2d2d0fb049c364e8bd0db8c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17646088 |
PQID | 19613446 |
PQPubID | 23462 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_68352579 proquest_miscellaneous_19613446 crossref_primary_10_1016_j_ijantimicag_2007_06_005 pubmed_primary_17646088 pascalfrancis_primary_19163889 elsevier_sciencedirect_doi_10_1016_j_ijantimicag_2007_06_005 elsevier_clinicalkeyesjournals_1_s2_0_S0924857907002725 |
PublicationCentury | 2000 |
PublicationDate | 2007-11-01 |
PublicationDateYYYYMMDD | 2007-11-01 |
PublicationDate_xml | – month: 11 year: 2007 text: 2007-11-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | London Amsterdam New York, NY |
PublicationPlace_xml | – name: Amsterdam – name: London – name: New York, NY – name: Netherlands |
PublicationTitle | International journal of antimicrobial agents |
PublicationTitleAlternate | Int J Antimicrob Agents |
PublicationYear | 2007 |
Publisher | Elsevier B.V Elsevier |
Publisher_xml | – name: Elsevier B.V – name: Elsevier |
References | Zhang, Wang, Jiang (bib10) 2000; 9 Craig (bib3) 1998; 26 Wang, Peng, Xiao (bib8) 2001; 6 Wang, Chen (bib1) 2005; 51 Ludwig, Konkoly-Thege, Kuti (bib14) 2006; 28 Kuti, Nicolau (bib5) 2005; 53 Zong, Xiao, Zhang (bib9) 1994; 10 Zhang, Wang, Zhang (bib11) 1995; 13 DeRyke, Kuti, Nicolau (bib6) 2007; 27 Bradley, Dudley, Drusano (bib4) 2003; 22 Hirakata, Matsuda, Miyazaki (bib2) 2005; 52 Drusano, Preston, Hardalo (bib13) 2001; 45 Tan, Sun, Yang (bib12) 1995; 6 Lodise, Lomaestro, Drusano (bib15) 2007; 44 Zhao, Li, Zhang (bib7) 2004; 20 Zhang (10.1016/j.ijantimicag.2007.06.005_bib10) 2000; 9 Tan (10.1016/j.ijantimicag.2007.06.005_bib12) 1995; 6 Zhao (10.1016/j.ijantimicag.2007.06.005_bib7) 2004; 20 Ludwig (10.1016/j.ijantimicag.2007.06.005_bib14) 2006; 28 Zhang (10.1016/j.ijantimicag.2007.06.005_bib11) 1995; 13 Hirakata (10.1016/j.ijantimicag.2007.06.005_bib2) 2005; 52 Lodise (10.1016/j.ijantimicag.2007.06.005_bib15) 2007; 44 DeRyke (10.1016/j.ijantimicag.2007.06.005_bib6) 2007; 27 Drusano (10.1016/j.ijantimicag.2007.06.005_bib13) 2001; 45 Kuti (10.1016/j.ijantimicag.2007.06.005_bib5) 2005; 53 Bradley (10.1016/j.ijantimicag.2007.06.005_bib4) 2003; 22 Wang (10.1016/j.ijantimicag.2007.06.005_bib8) 2001; 6 Zong (10.1016/j.ijantimicag.2007.06.005_bib9) 1994; 10 Craig (10.1016/j.ijantimicag.2007.06.005_bib3) 1998; 26 Wang (10.1016/j.ijantimicag.2007.06.005_bib1) 2005; 51 |
References_xml | – volume: 51 start-page: 201 year: 2005 end-page: 208 ident: bib1 article-title: Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002 publication-title: Diagn Microbiol Infect Dis contributor: fullname: Chen – volume: 26 start-page: 1 year: 1998 end-page: 12 ident: bib3 article-title: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men publication-title: Clin Infect Dis contributor: fullname: Craig – volume: 20 start-page: 161 year: 2004 end-page: 164 ident: bib7 article-title: Pharmacokinetics of meropenem single dose intravenous in healthy volunteers publication-title: Chin J Clin Pharmacol contributor: fullname: Zhang – volume: 6 start-page: 25 year: 1995 end-page: 26 ident: bib12 article-title: Comparison of pharmacokinetics of domestic and imported ciprofloxacin injection in healthy volunteers publication-title: Zhongguo Yaofang contributor: fullname: Yang – volume: 27 start-page: 333 year: 2007 end-page: 342 ident: bib6 article-title: Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against publication-title: Pharmacotherapy contributor: fullname: Nicolau – volume: 9 start-page: 75 year: 2000 end-page: 78 ident: bib10 article-title: Pharmacokinetics of intravenously administered cefoperazone/sulbactam in normal volunteers publication-title: Chin J Clin Pharm contributor: fullname: Jiang – volume: 45 start-page: 13 year: 2001 end-page: 22 ident: bib13 article-title: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint publication-title: Antimicrob Agents Chemother contributor: fullname: Hardalo – volume: 52 start-page: 323 year: 2005 end-page: 329 ident: bib2 article-title: Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia–Pacific region (SENTRY 1998–2002) publication-title: Diagn Microbiol Infect Dis contributor: fullname: Miyazaki – volume: 10 start-page: 385 year: 1994 end-page: 388 ident: bib9 article-title: The pharmacokinetics of ceftazidime in burned patients publication-title: Zhonghua Zhengxing Shangshao Waike Zazhi contributor: fullname: Zhang – volume: 13 start-page: 195 year: 1995 end-page: 198 ident: bib11 article-title: Clinical pharmacokinetic study on cephalosporins and the proposed therapeutic regimens publication-title: Zhongguo Chuanranbing Zazhi contributor: fullname: Zhang – volume: 28 start-page: 433 year: 2006 end-page: 438 ident: bib14 article-title: Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against publication-title: Int J Antimicrob Agents contributor: fullname: Kuti – volume: 44 start-page: 357 year: 2007 end-page: 363 ident: bib15 article-title: Piperacillin–tazobactam for publication-title: Clin Infect Dis contributor: fullname: Drusano – volume: 53 start-page: 281 year: 2005 end-page: 287 ident: bib5 article-title: Making the most of surveillance studies: summary of the OPTAMA Program publication-title: Diagn Microbiol Infect Dis contributor: fullname: Nicolau – volume: 6 start-page: 391 year: 2001 end-page: 393 ident: bib8 article-title: Pharmacokinetics of imipenem in burned patients publication-title: Xinan Guofang Yiyao contributor: fullname: Xiao – volume: 22 start-page: 982 year: 2003 end-page: 992 ident: bib4 article-title: Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation publication-title: Pediatr Infect Dis J contributor: fullname: Drusano – volume: 26 start-page: 1 year: 1998 ident: 10.1016/j.ijantimicag.2007.06.005_bib3 article-title: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men publication-title: Clin Infect Dis doi: 10.1086/516284 contributor: fullname: Craig – volume: 6 start-page: 391 year: 2001 ident: 10.1016/j.ijantimicag.2007.06.005_bib8 article-title: Pharmacokinetics of imipenem in burned patients publication-title: Xinan Guofang Yiyao contributor: fullname: Wang – volume: 20 start-page: 161 year: 2004 ident: 10.1016/j.ijantimicag.2007.06.005_bib7 article-title: Pharmacokinetics of meropenem single dose intravenous in healthy volunteers publication-title: Chin J Clin Pharmacol contributor: fullname: Zhao – volume: 22 start-page: 982 year: 2003 ident: 10.1016/j.ijantimicag.2007.06.005_bib4 article-title: Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation publication-title: Pediatr Infect Dis J doi: 10.1097/01.inf.0000094940.81959.14 contributor: fullname: Bradley – volume: 6 start-page: 25 year: 1995 ident: 10.1016/j.ijantimicag.2007.06.005_bib12 article-title: Comparison of pharmacokinetics of domestic and imported ciprofloxacin injection in healthy volunteers publication-title: Zhongguo Yaofang contributor: fullname: Tan – volume: 28 start-page: 433 year: 2006 ident: 10.1016/j.ijantimicag.2007.06.005_bib14 article-title: Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2006.07.014 contributor: fullname: Ludwig – volume: 13 start-page: 195 year: 1995 ident: 10.1016/j.ijantimicag.2007.06.005_bib11 article-title: Clinical pharmacokinetic study on cephalosporins and the proposed therapeutic regimens publication-title: Zhongguo Chuanranbing Zazhi contributor: fullname: Zhang – volume: 52 start-page: 323 year: 2005 ident: 10.1016/j.ijantimicag.2007.06.005_bib2 article-title: Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia–Pacific region (SENTRY 1998–2002) publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2005.04.004 contributor: fullname: Hirakata – volume: 10 start-page: 385 year: 1994 ident: 10.1016/j.ijantimicag.2007.06.005_bib9 article-title: The pharmacokinetics of ceftazidime in burned patients publication-title: Zhonghua Zhengxing Shangshao Waike Zazhi contributor: fullname: Zong – volume: 44 start-page: 357 year: 2007 ident: 10.1016/j.ijantimicag.2007.06.005_bib15 article-title: Piperacillin–tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy publication-title: Clin Infect Dis doi: 10.1086/510590 contributor: fullname: Lodise – volume: 53 start-page: 281 year: 2005 ident: 10.1016/j.ijantimicag.2007.06.005_bib5 article-title: Making the most of surveillance studies: summary of the OPTAMA Program publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2005.10.004 contributor: fullname: Kuti – volume: 51 start-page: 201 year: 2005 ident: 10.1016/j.ijantimicag.2007.06.005_bib1 article-title: Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002 publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2004.09.001 contributor: fullname: Wang – volume: 9 start-page: 75 year: 2000 ident: 10.1016/j.ijantimicag.2007.06.005_bib10 article-title: Pharmacokinetics of intravenously administered cefoperazone/sulbactam in normal volunteers publication-title: Chin J Clin Pharm contributor: fullname: Zhang – volume: 45 start-page: 13 year: 2001 ident: 10.1016/j.ijantimicag.2007.06.005_bib13 article-title: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.45.1.13-22.2001 contributor: fullname: Drusano – volume: 27 start-page: 333 year: 2007 ident: 10.1016/j.ijantimicag.2007.06.005_bib6 article-title: Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004 publication-title: Pharmacotherapy doi: 10.1592/phco.27.3.333 contributor: fullname: DeRyke |
SSID | ssj0015345 |
Score | 2.0624912 |
Snippet | Abstract Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese... Using minimum inhibitory concentration (MIC) data derived from a Chinese national surveillance study and pharmacokinetic data collected in Chinese individuals,... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 452 |
SubjectTerms | Acinetobacter baumannii Anti-Bacterial Agents - pharmacokinetics Antibiotic Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial resistance Biological and medical sciences China Computer Simulation Enterobacteriaceae Enterobacteriaceae - drug effects Enterobacteriaceae Infections - drug therapy Enterobacteriaceae Infections - microbiology Escherichia coli Humans Infectious Disease Klebsiella pneumoniae Medical sciences Microbial Sensitivity Tests Monte Carlo Method Pharmacodynamics Pharmacology. Drug treatments Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology |
Title | Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004 |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0924857907002725 https://dx.doi.org/10.1016/j.ijantimicag.2007.06.005 https://www.ncbi.nlm.nih.gov/pubmed/17646088 https://search.proquest.com/docview/19613446 https://search.proquest.com/docview/68352579 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYhpaVQSpu-tm22Uyg5xV0_ZMuGXkJoum0hBJpAbkKy5MWBepfYOewlv70zkh0nhIVAb-tFlsfSSDNjffMNY18SGykThcRTaaqAq8IGik7ZU4U-UlIKIgUjtMVxNj_jv87T8y12OOTCEKyy3_v9nu526_6fWT-as1Vdz_6EBdFxCYzuKLaKKdGco_lDnf56fQPzwAXtChVT44BaP2GfR4xXfYHi15SXv-jZDOloIt1ko56tVIsjV_mSF5t9Umebjl6w571TCQde7pdsyzY77LEvM7neYXsnnp96vQ-nY7pVuw97cDIyV69fsevh0vg69eBx4qC6ATYAywpaIn2C_pWIxgk1GNQCW7Qd_LhUf4PGLhyfOGjPBa2A1A2H2RqgfBZwVbuhboBAa9iVoR_8NTs7-n56OA_6Ag1BmaaiC6zOdGx5lFcmEaWyVULs8QK9ljTPoyq1QpUYARc2NrEJK43RSJlk3ObahEbnZfKGbTfLxr5jgNe6MDypMCLneaxz7ARjRSOUCgsTpRMWD1MiV56HQw4AtQt5ax6prqaQDqyHN4lh8uSQaIpbo237ddrKSLaxDOU9XZqwbzd33lFHiZbmIQ-e3lGVUeSC_N-8mLBPg-5IXM90SKMau7xCiQp0sDBG39wiyx2FLfbx1ivd2LvIeIZm4_3_Sf-BPXVfsF3G5Ue23V1e2V10vTo9dWtryh4d_Pw9P_4He5Qvgw |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7ShLaBUto0bbaPRIWSU8z6JcuCXkJoumnSJdAN5CZkS14cqHeJncNe-ts7Y9lxQ1ko9GYZaazHjDRjzXwD8CmygTaBTziVpvBiLa2n6Zada9SRolwQKBh5W0yTyVX87Zpfb8BJHwtDbpXd3u_29Ha37t6Mu9kcL8ty_MOXBMcl0Loj2yrkj2ALtQGJ0rl1fHY-md5fJvCozVVM9T1q8AQ-Dm5e5Q2OoKTQ_HkHaEi3E3zdMfVsqWucvMJlvVivlrbH0-kLeN7plezYdf0lbNhqBx67TJOrHTi8dBDVqyM2GyKu6iN2yC4H8OrVK_jVF41LVc-cqzjTTe85wBYFqwn3iXVDIiQnZGKm51ijbtjXW_3Tq-y8hRRnmYOD1ow4DmfaGkYhLaxN3M3KipHfGpIy9BDvwtXpl9nJxOtyNHg556LxbJZkoY2DtDCRyLUtIgKQF6i48DQNCm6FztEIljY0ofGLDA2SPEpim2bGN1maR69hs1pUdg8YljNp4qhAozxOwyxFImguGqG1L03ARxD2S6KWDopD9T5qN-qPdaTUmkK1_nrYSPSLp_pYU9wdbd2Jaq0CVYfKV3-x0wg-37d8wJEKD5t_-fD-A1YZuixJBU7lCA563lEo0nRPoyu7uMMeSdSx0ExfXyNJWxRbpPHGMd1AXSRxgifH2__r_QE8ncy-X6iLs-n5O9huf2i3AZjvYbO5vbMfUBNrsv1O0n4DzLYyNw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacodynamic+target+attainment+of+seven+antimicrobials+against+Gram-negative+bacteria+collected+from+China+in+2003+and+2004&rft.jtitle=International+journal+of+antimicrobial+agents&rft.au=Wang%2C+Hui&rft.au=Zhang%2C+Bo&rft.au=Ni%2C+Yuxing&rft.au=Kuti%2C+Joseph+L&rft.date=2007-11-01&rft.issn=0924-8579&rft.volume=30&rft.issue=5&rft.spage=452&rft.epage=457&rft_id=info:doi/10.1016%2Fj.ijantimicag.2007.06.005&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09248579%2FS0924857907X01729%2Fcov150h.gif |